Sirigen develops a high-sensitivity fluorescence technology intended to boost performance of diagnostic tools used to analyse and manage diseases such as HIV and leukaemia. The company plans to use new financing to commercialize that fluorescence technology. Sirigen is based in Ringwood, UK, and also operates a US subsidiary in San Diego, CA. The firm announced board and leadership changes alongside the funding, reflecting a push toward commercialization. Financially, Sirigen completed a new financing round raising £3.83m to support its commercial efforts. No operating metrics or prior revenue figures were disclosed in the article.

Total raised

$6M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2010